New hope for rare blood cancer: targeted drug plus chemotherapy under study
NCT ID NCT06630091
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy (CHOP) can better control newly diagnosed peripheral T cell lymphoma, a rare and aggressive blood cancer. About 30 adults will receive the combination, and researchers will monitor side effects and how well the cancer responds. The study is currently recruiting at MD Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
golidocitinib (a targeted drug) combined with standard chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone)
What this could lead to
If successful, this could offer a new first-line treatment option for peripheral T cell lymphoma, potentially improving disease control and survival.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and it is not yet known if it works better than standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••